EVO100 Gel
Evofem is collaborating with Orion Biotechnology to evaluate the combination of Orion’s novel CCR5 antagonist, OB-002, and Phexxi® with the goal of developing a Multipurpose Prevention Technology (MPT) product candidate for indications including the prevention of human immunodeficiency virus (HIV) in women.
Development Stage:
Clinical – Phase 3 Trial (C3)
Hormonal/Non-Hormonal:
Non-Hormonal
Delivery Route & Method:
Topical - Gel-Vaginal
Mechanism of Action:
Vaginal pH modulator
Developer:
- Evofem Biosciences, Inc.
Funding:
- Evofem Biosciences, Inc.
Funding Mechanism:
The Phase 3 EVOGUARD study is funded in part by a strategic investment in Evofem by Adjuvant Capital, LLC.
Active Ingredient(s):
- Citric Acid
- L-lactic Acid
- Potassium Bitartrate
Product Indication(s):
- Pregnancy
- Chlamydia and gonorrhea under clinical investigation
Useful Links:
- http://www.evofem.com/in-development/
- http://www.evofem.com/our-product/
- https://clinicaltrials.gov/ct2/show/NCT01306331?term=Amphora+Gel&rank=1
- https://www.evoguardstudy.com/ct/
- https://clinicaltrials.gov/ct2/show/NCT03243305?term=Amphora+Gel&draw=2&rank=4
- https://clinicaltrials.gov/ct2/show/NCT04553068?term=EVO100&draw=2&rank=1